3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
47
Breast Neoplasms
6
Leiomyoma
5
Neoplasms
4
Adenocarcinoma
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Prostatic Diseases
1
Premenopausal Breast Cancer
1
Polycystic Ovary Syndrome
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Myofibroma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lower Urinary Tract Symptoms
1
Infertility
1
Hodgkin Disease
1
Hereditary Sensory and Autonomic Neuropathies
1
Genital Neoplasms, Male
1
Carcinoma
1
Breast Neoplasms, Male
1
Advanced Prostate Cancer
1
Advanced Prostate Adenocarcinoma
1
Interventions
exemestane
2
Letrozole
2
seviteronel
1
sargramostim
1
ribociclib
1
methyl N-acetylsibirosaminide
1
elacestrant
1
Trastuzumab
1
Tamoxifen
1
Suspensions
1
Receptor Protein-Tyrosine Kinases
1
Presenilin-1
1
Pemetrexed
1
Leuprolide
1
Injections
1
HER2 peptide (369-377)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Goserelin
1
Fentanyl
1
Anastrozole
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms, Male
×
Leuprolide
×
Clear all
NCT05827081
2026-06-03
Adjuvant WIDER
Novartis
Phase 3
Recruiting
1,400 enrolled